Plant-Based rBuChE Production for Scalable Nerve Agent Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant butyrylcholinesterase (rBuChE) are inadequate for large-scale, cost-effective, and rapid production, particularly for nerve agent protection, due to limitations in scalability, sialylation, and tetramer formation, which are essential for optimal potency and immunogenic response.
Innovation Solution
A plant-based transfection procedure is used to produce rBuChE with sialylation and tetramer formation, employing vectors with specific nucleotide sequences to achieve high levels of sialylation and tetramerization, enabling scalable and cost-effective production of rBuChE with enhanced pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional mammalian cell culture methods are used to produce rBuChE, then the production process is well-established, but scalability and production cost are limited
Solution Approach 1:
The patent uses plant cells as a simplified copying system to produce rBuChE, replacing complex mammalian cell culture with a more scalable plant-based platform that can be cultivated using established agricultural techniques, thereby improving scalability while reducing manufacturing complexity
Solution Approach 2:
The patent changes the production system from mammalian cells to plant cells, fundamentally altering the biological parameters of the production process. This parameter change enables scalable production through plant cultivation while maintaining the ability to produce properly folded and modified rBuChE protein
2Duration of action of moving object
If rBuChE is produced without sufficient sialylation, then production is simpler, but serum half-life is reduced
Solution Approach 1:
The plant-based expression system self-provides the necessary sialylation machinery to modify rBuChE with sialic acid residues. The plant cells naturally possess the glycosylation and sialylation pathways required to produce fully modified rBuChE with extended serum half-life, eliminating the need for complex external modification processes
Solution Approach 2:
The plant cells perform sialylation as a preliminary action during the protein production process itself, rather than as a subsequent separate step. This preliminary modification ensures that rBuChE is produced with the necessary sialic acid residues already attached, extending serum half-life without adding post-production complexity
3Reliability
If rBuChE is produced without tetramer formation, then production is simpler, but potency against organophosphorus agents is reduced
Solution Approach 1:
The plant-based system self-organizes rBuChE into tetrameric structures through natural protein-protein interactions that occur during expression and purification. The plant cellular environment provides the appropriate conditions for spontaneous tetramer formation, ensuring high potency without requiring complex external oligomerization control mechanisms
Solution Approach 2:
The patent changes the expression conditions in the plant-based system to favor tetramer formation, altering parameters such as protein concentration, pH, and ionic strength during production. These parameter changes promote spontaneous self-assembly into tetramers, ensuring reliable potency while avoiding complex control mechanisms
4Productivity
If plant-based transfection is used for rapid production, then scalability improves, but manufacturing precision must be maintained
Solution Approach 1:
The patent optimizes specific parameters of the plant transfection and expression system, including Agrobacterium infiltration conditions, plant growth parameters, and harvest timing. These parameter optimizations ensure consistent production of sialylated tetrameric rBuChE while maintaining rapid scalability through plant-based cultivation
Solution Approach 2:
The patent implements quality control measures with feedback mechanisms to monitor sialylation levels and tetramer formation during plant-based production. By measuring these parameters and adjusting cultivation or purification conditions accordingly, the system maintains manufacturing precision while leveraging the scalability of plant systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The plant-based system provides a rapid, scalable, and cost-effective method for producing rBuChE with high sialylation and tetramerization, resulting in a product with extended serum half-life and improved efficacy against organophosphorus agents, addressing the limitations of traditional mammalian cell culture methods.
Implementation Method 1
providing said plant, plant cell, or both, with at least one vector capable of expressing said butyrylcholinesterase
Implementation Method 2
incubating said plant, plant cell, or both, at conditions that cause the synthesis of said butyrylcholinesterase
Implementation Method 3
the generation of sialylated glycans, tetramer formation, or both, on said butyrylcholinesterase
Implementation Method 4
generation of sialylated glycans... on said butyrylcholinesterase to form a butyrylcholinesterase product exhibiting at least one of sialylation and tetramer formation
Implementation Method 5
A plant-based transfection procedure is used to produce rBuChE with sialylation and tetramer formation
Data Source
Figure 1
Figure 2
Figure 3A~3C
AI summary
A new, reliable, easily scalable and reproducible method for the production of recombinant butyrylcholinesterase (rBuChE) is provided. Through the utilization of a plant transfection procedure, various plant strains have been shown to generate effective and scalable amounts of rBuChE under acceptable manufacturing processes to permit reliable levels of such enzymes for desired nerve agent protection requirements (including tetrameric products). As well, such methods in engineered plant lines have shown suitable production of these enzymes in tetramer form with glycan formation and sialyalation (for terminal groups) to allow for optimal potency against organophosphorus agent exposure as well as proper immunogenic response within the plant sources. The overall production method, including the transfection and production within mammalian cells, as well as the process steps involved for such a reliable sourcing platform from plants is thus encompassed within the invention.